

## Medical Applications of Evolutionary Computation

**Stephen L. Smith**  
**University of York**  
**York, UK**  
**stephen.smith@york.ac.uk**

Permission to make digital or hard copies of part or all of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. Copyrights for third-party components of this work must be honored. For all other uses, contact the Owner/Author.

Copyright is held by the owner/author(s).  
GECCO'16 Companion, July 20-24, 2016, Denver, CO, USA  
ACM 978-1-4503-4323-7/16/07.  
<http://dx.doi.org/10.1145/2908961.2931730>



1

## Welcome

- ❖ **Stephen L. Smith** received a BSc in Computer Science and then an MSc and PhD in Electronic Engineering from the University of Kent, UK. He is currently a Reader in the Department of Electronics at the University of York, UK.
- ❖ Steve's main research interests are in developing novel representations of evolutionary algorithms particularly with application to problems in medicine. His work is currently centered on the diagnosis of neurological dysfunction and analysis of mammograms.
- ❖ Steve is co-founder and organizer of the MedGEC Workshop, which is now in its twelfth year. He is also co-editor of a book on the subject (John Wiley, November 2010).
- ❖ Steve is associate editor for the journal Genetic Programming and Evolvable Machines and a member of the editorial board for the International Journal of Computers in Healthcare and Neural Computing and Applications.
- ❖ In 2013 Steve co-founded ClearSky Medical Diagnostics, a university spinout company for developing medical devices that exploit genetic programming technologies.



**ClearSky**<sup>®</sup>  
medical diagnostics  
**UNIVERSITY of York**

2

## The City of York




3

## The University of York



4

## *The University of York*



5

## *Overview*

- ❖ Introduction to medical applications of EC
  - how these differ from other real-world applications
- ❖ Overview of previous work
  - from a medical and EC point of view
- ❖ Case examples of medical applications
- ❖ Practical advice on how to get started
  - choosing an application and obtaining good data
- ❖ Summary

6

## *Introduction*

- ❖ Challenging application area
  - often no reliable “ground truth” or “gold standard”
  - access to data difficult
  - multiple ethical considerations
- ❖ Opportunities
  - unexplored territory
  - funding and publications
  - make a difference

7

## *Previous Work*



- ❖ Medical Imaging and Signal Processing
- ❖ Data Mining Medical Data and Patient Records
- ❖ Modelling and Simulation of Medical Processes
- ❖ Clinical Expert Systems and Knowledge-based Systems
- ❖ Clinical Diagnosis and Therapy

8

## Medical Imaging and Signal Processing

Ballerini and Bocchi [1]

- ❖ Automated image segmentation
- ❖ Bone age assessment
  - to detect abnormality in skeletal growth
- ❖ Multiple genetic snakes
  - planar active contours optimised by GAs
  - elastic force connects adjacent snakes




Source: Ballerini and Bocchi [1]

9

## Medical Imaging and Signal Processing

Mañana, González and Romero [2]

- ❖ Image Registration
- ❖ Intra-oral radiographs
- ❖ Distributed adaptive GA
  - to find an optimal affine
- ❖ Genome
  - 4 floating point numbers
    - scale factor
    - rotational angle
    - X & Y translations




Source: Mañana, González and Romero [2]

10

## Data Mining Medical Data and Patient Records

Ghannad-Rezaie et al. [3]

- ❖ Surgery candidate selection
  - for temporal lobe epilepsy
  - integrates a classifier with a particle swarm algorithm (PSO)
- ❖ Compared with:
  - ant colony optimisation (ACO)
  - Bayesian Belief Network (BBN)
  - C4.5 (a decision tree approach)
  - Local Linear Model Tree (LOLIMOT)




Source: Ghannad-Rezaie et al. [3]

11

## Modelling and Simulation of Medical Processes

Bosman and Alderliesten [4]

- ❖ Medical simulation
  - for minimally invasive vascular intervention
  - used to train clinicians
- ❖ Minimisation of energy
  - associated with trajectory of guide wire
  - iterative density estimation evolutionary
  - accurate and closer to real-time simulation of the intervention




Source: Bosman and Alderliesten [4]

12

## Clinical Expert Systems and Knowledge-based Systems

Koutsojannis and Hatzilygeroudis [5]

- ❖ Diagnosis and treatment of blood gas disturbances
  - observed in intensive care unit patients
- ❖ Fuzzy expert system incorporating an EA
  - differential EA fine-tunes membership functions of the fuzzy variables



Source: Koutsojannis and Hatzilygeroudis [5]

13

## Why Consider a Medical Application?

- ❖ Interesting
  - real problems
  - potential to help real people
  - cross-disciplinary collaborations
- ❖ Good source of funding
  - government
  - charities
  - commercialization opportunities
- ❖ Good for publications
  - exploit both engineering and medical literatures

14

## Choosing a Medical Application

- ❖ Review the field
  - through the medical and engineering literature
- ❖ Choose a *novel* application area
  - with a clinical need (medical or financial!)
- ❖ Contact a health professional
  - go and talk to them
- ❖ Evaluate the scope for obtaining data
  - and a “gold standard” or “ground truth”

15

## Datasets

- ❖ The performance of any evolutionary algorithm is only as good as the data it is trained on
  - often no definitive clinical test for condition under investigation
  - datasets usually involve subjective clinical assessment
  - often have missing or corrupted values
    - resulting in insufficient good data for statistical
    - can be ameliorated by the use of k-fold cross-validation

16

## Datasets


### ❖ When subjective evaluation is involved:

- engage multiple assessors
  - to provide greater confidence
- agree a consistent marking protocol
  - several standards usually in use
- gather data from multiple sites
  - to compensate for local marking practice
  - to sample representative demographic population

### ❖ Engage a health statistician **before** you start


17

## Complex Figure Copying Test




18

## Example Patient Drawings



19

## Subjective Mark Scheme



20

## Choice of Evolutionary Algorithm

- ❖ Many to choose from
- ❖ Choice often based on:
  - previous experience
  - match to data representation
  - performance in previous similar applications
- ❖ Consider conventional statistical analysis
  - comparison of performance
  - justification for the use of an EA
  - understand the nature of the data
- ❖ Ensembles of EAs have potential


21

## Cartesian Genetic Programming (CGP)

- ❖ Form of genetic programming
  - Miller and Thomson (1997)


- ❖ Genotype is a list of integers

- that represent the program elements
- how they are connected together




- ❖ Representation - a directed graph

- simple, flexible and convenient for many problems




22

## Example CGP Network



0 1 1 1 1 3 0 2 2 2 3 1 5


23



24


## Implicit Context Representation

- ❖ Consider standard GP
- ❖ Parse tree structure
- ❖ Mutation and crossover




25

## Enzyme Genetic Programming (Lones and Tyrrell)



26




27

## Implicit Context Representation for CGP


Mutation of components'

- ❖ Binding sites' shapes
- ❖ Function




28

## Formation of Network




29

## Formation of Network




30

## Formation of Network




31

## Formation of Network




32

## Formation of Network



33

## Data Input




❖ Many different possible modalities, e.g.

- image
- continuous and discrete measurements
- text

34

## Desired Output



- Often a two class problem – disease/no disease
  - Sometimes multiclass (typically 5)
- Requires thresholding of output or other approaches

35

## Fitness Function

❖ In clinical studies often based on sensitivity and specificity

- sensitivity =  $TP/P$
- specificity =  $TN/N$

Where:

TP number of true positive instances correctly classified

TN number of true negative instances correctly classified


P is number of positive instances that truly exist

N is number of negative instances that truly exist

36

## Choice of Threshold Value

- Can be used to weight classification
- According to the cost associated with a misclassification
- Often summarised using ROC curves




kakau. Released under the GNU Free Documentation License.

37

## ROC Analysis

### ❖ Receiver Operating Characteristic (ROC) curves:




Slide: Mic Lones

38

## ROC Analysis

### ❖ Receiver Operating Characteristic (ROC) curves:




Slide: Mic Lones

39

## ROC Analysis

### ❖ Receiver Operating Characteristic (ROC) curves:




Slide: Mic Lones

40

## ROC Analysis

### ❖ Receiver Operating Characteristic (ROC) curves:




Slide: Mic Lones

41

## ROC Analysis

### ❖ Receiver Operating Characteristic (ROC) curves:




Slide: Mic Lones

42

## ROC Analysis

### ❖ Receiver Operating Characteristic (ROC) curves:




Slide: Mic Lones

43

## ROC Analysis

### ❖ Receiver Operating Characteristic (ROC) curves:




Slide: Mic Lones

44

## ROC Analysis

### ❖ Receiver Operating Characteristic (ROC) curves:




Slide: Mic Lones

45

## ROC Analysis

### ❖ Receiver Operating Characteristic (ROC) curves:




Slide: Mic Lones

46

## ROC Analysis

### ❖ Receiver Operating Characteristic (ROC) curves:

- Area Under Curve (AUC)
  - Probability of ranking a class member higher than a non-member
  - i.e.  $p[ C(\text{cancer}) > C(\text{non-cancer}) ]$




Slide: Mic Lones

47

## ROC Analysis

### ❖ Receiver Operating Characteristic (ROC) curves:

- Area Under Curve (AUC)
  - Probability of ranking a class member higher than a non-member
  - i.e.  $p[ C(\text{cancer}) > C(\text{non-cancer}) ]$
  - AUC of 0.5 equivalent to random classification
  - A classifier with  $AUC = n$  has the same power as one with  $AUC = 1 - n$
  - AUCs recently attracted criticism



Slide: Mic Lones

48

## ROC Analysis

### ❖ Multi-class ROC analysis:

- Hand and Till, 2001:

$$AUC_{\text{multiclass}} = \frac{2}{|C|(|C| - 1)} \sum_{\{c_i, c_j\} \in C} AUC(c_i, c_j)$$

- $\approx$  mean of AUCs for each pair of classes
- Direction of AUCs ( $>$  or  $<$  0.5) is important
  - i.e. must separate classes in the correct order

D. Hand and R. Till. A simple generalization of the area under the ROC curve to multiple class classification problems. *Machine Learning*, 45(2):171-186, 2001.

49

## Case Example 1: Breast Cancer

([www.breastcanceruk.org.uk/statistics/2004-6](http://www.breastcanceruk.org.uk/statistics/2004-6))

- ❖ 207,000 women diagnosed in the US in 2010
  - 40,000 died as a result of the disease
- ❖ 1 in 9 women will suffer from breast cancer at some time in their life
- ❖ Most commonly diagnosed cancer in women under the age of 35
- ❖ Accounts for some 25% of all cancer cases in women worldwide

50

## Mammograms

- ❖ Assessed subjectively
- ❖ Size, shape and texture of
  - microcalcifications
  - spiculated masses


51

## Microcalcifications

- ❖ Calcium deposits
  - secretions from ductal structures
- ❖ Occur in clusters
- ❖ 40-50% cancerous
- ❖ Discriminated by:
  - shape
  - size
  - texture
  - distribution

52

## Microcalcifications




Example cluster of malignant microcalcifications

Example cluster of benign microcalcifications

(Images courtesy of the *Radiology Assistant*: [www.radiologyassistant.nl](http://www.radiologyassistant.nl))

53

## Spiculated Masses



Example spiculated mass

(Image courtesy of the *Radiology Assistant*: [www.radiologyassistant.nl](http://www.radiologyassistant.nl))

54

## Datasets

- ❖ Several publically available datasets of mammograms
  - Mammographic Image Analysis Society (MIAS) Database
  - University of South Florida Digital Mammography Database (USFDMD)
  - Lawrence Livermore/University of California (LLNL/UCSF) Database
- ❖ Many privately constructed datasets

55

## Datasets

- ❖ All have their disadvantages
- ❖ Lack consistency in:
  - classification
  - demographic spread
  - diagnosis
  - supporting diagnostic information
  - digitization
  - resolution
  - file format

56

## *Using Existing Datasets*

- ❖ Using other peoples datasets may have implications!
- ❖ LLNL/UCSF database
- ❖ From “Somewhere in England”

57


## *Constructing a New Dataset*

- ❖ Requires:
  - clinical cooperation
  - authority
  - suitable software tools
    - especially, the user interface

58

## *Regions of Interest (ROI)*

- ❖ Regions showing microcalcifications are identified (128x128 pixel)
- ❖ These are divided into smaller sections called ‘parts’ (8x8 pixels)




## *Application of CGP*

- ❖ CGP as an optimizer
- ❖ CGP as a feature extractor and classifier

60

## CGP as an Optimizer

Hope, Smith and Munday [6]




61

## Spatial Gray Level Dependence Matrix


- ❖ Also known as spatial gray co-occurrence matrix
- ❖ Considers positional information of pixels
- ❖ Following features from the SGLD matrices
  - at  $45^\circ$  ,  $90^\circ$  ,  $135^\circ$  and  $180^\circ$
  - maximum value
  - second moment
  - third moment

62

## CGP as Feature Extractor and Classifier




63




Walker, Völk, Smith and Miller [7]

64

[illegible]

65

- ❖ Use OpenCV image functions as CGP function set (Simon Harding, CGP-IP)



66

- ❖ Common, chronic, progressive neurodegenerative brain disease
- ❖ Affects the control of muscles
- ❖ Incidence of 1 person in 1000
  - about 1 person in 100 over the age of 60
- ❖ Insufficient formation and action of dopamine

67

- ❖ Tremor
  - 3Hz-8Hz
- ❖ Rigidity
  - cogwheel
- ❖ Bradykinesia
  - slowing in movement
- ❖ Postural instability
  - poor balance

68

## Conventional Diagnosis of Parkinson's Disease

### ❖ Diagnosis of idiopathic Parkinson's Disease

- based on clinical features
- often very subjective
- poor sensitivity - up to 25% error in diagnosis
- PET scans to detect decreased dopamine activity

### ❖ Medication


- L-dopa, artificial dopamine
- has limited life due to feedback inhibition
- eventually becomes counterproductive.

69

## Computer-Based Assessment

### ❖ Based on neuropsychological tasks

- figure copying tasks
- finger tapping tasks
- measurement of tremor at rest



### ❖ Patient's movements digitised in real-time

70


## Data Analysis

### ❖ Initially, results poor



### ❖ Closer inspection of patient data

- patients with Parkinson's disease
- controls with no known neurodegenerative condition

71




72




## Figure-Copying Tasks

- ❖ Choice of task domain important
- ❖ Used to emphasize symptoms under consideration



75


## Velocity Profile of Patient's Response



76

## Identification of Features


- ❖ Features unique to Parkinson's patients
  - determined through visual inspection
- ❖ Indicates a two-stage acceleration
- ❖ Consistent with hesitation
  - Bradykinesia?



77


Patient  
Measurements

Evolutionary Algorithm



78

## Example Results






79

## Finger Tapping Task



80



### Case Example 3: Thyroid cancer

Lones, Smith, Harris et al. [8]

❖ Incidence of 1 in 842 for men, 1 in 324 for women\*

❖ 4 types, in order of increasing aggressiveness:

- **Papillary carcinoma**
  - 70-80% of cases, low mortality rate
- **Follicular carcinoma**
  - 10-15%, fairly low mortality rate
- **Medullary carcinoma**
  - 5-10%, moderate mortality rate
- **Anaplastic carcinoma**
  - <5%, high mortality rate

\*UK Thyroid Cancer Statistics, Cancer Research UK, 2008.


84

## Raman Spectroscopy

- ❖ Optical methodology
  - Uses monochromatic light
  - Measures energy states
- ❖ Advantages
  - Detailed
  - Fast
  - Non-invasive
  - Non-destructive
  - Uses small samples
- ❖ Disadvantages
  - Complex signals
  - Difficult to analyse

85


## Biochemical Spectra



J. De Gelder, K. De Gussem, P. Vandenabeele and Luc Moens, Reference Database of Raman spectra of biological molecules, *Journal of Raman Spectroscopy* 38:1133-1147, 2007.

86

## Thyroid Cell Lines




Class	Name	Cell Type	Samples
1	Nthy-ori 3-1	Normal follicular epithelial	30
2	K1	Papillary thyroid carcinoma	25
3	RO82-W-1	Follicular thyroid carcinoma	25
4	TT	Medullary thyroid carcinoma	24
5	8305C	Anaplastic thyroid carcinoma	25

87

## Methodology

- ❖ Evolve classifiers
  - Terminal set: Raman offsets {600,...,1800}
  - Function set: +, -, \*, mean, min, max, negate
- ❖ Using implicit context representation CGP [Smith, 2005]
  - Cartesian Genetic Programming [Miller and Thomson, 2000]
  - Implicit context representation [Lones and Tyrrell, 2002]
- ❖ Fitness is the ability to separate cancer classes
  - In order of biological aggressiveness
  - Measured using multi-class area under ROC curve

S. Smith et al. An implicit context representation for evolving image processing filters. *EvoISP* 2005.  
J. Miller and P. Thomson. Cartesian genetic programming. *EuroGP* 2000.  
M. Lones and A. Tyrrell. *Genetic Programming and Evolvable Machines* 3(2):193-217.




88

## Results



89

## Results



90

## Results


The 10 highest scoring classifiers

Expression	Test AUC
$out = \{885, 1001\} - 1607 - \max\{1656, 1117\}$	0.75
$out = (841 + 1002) - (836 + 1600) + (\max\{-622, 1657 * 1655\} - 1657 * 1655)$	0.75
$out = 780 - 1606 + (\max\{1002, 1084\} - (636 + 1664))$	0.74
$out = (1002 - 1661) - ((1607 - 1379)(625 - 1783)) - \max\{625, 636\}$	0.73
$out = -(\{-1001, 1270 + 1741\} + \{-999, 1606\})$	0.72
$out = -(-\{1002, 999\} + \{-1473, 1173\} - 1473 * (1599 + 723))$	0.72
$out = (636 * 1661 - \max\{878, 893\})(636 * 1661 - (1002 - 833))$	0.72
$out = -\{sub_1, \min\{833, \{1463, 636\}\}, sub_1, 1603 + 1661\}$ $sub_1 = -\max\{1685, 1002\}$	0.71
$out = (1001 - 713) + (1715 * 1751 - 636)$	0.71
$out = \{(1439 + \{1533, 1759\})^2, sub_1 - sub_2\} + (sub_1 - sub_2)$ $sub_1 = 1603 + 1757 + (833 - 1001)$ $sub_2 = \{1566, 964\}$	0.71

91


## Results

Raman shifts referenced by the 10 highest scoring classifiers



92

## Results



93


## Experimental Settings

- ❖ 50 runs, 50 generation limit, population of 500
- ❖ CGP grid size of 5x5
- ❖ Using training, validation and test sets

Function	Description
$x + y$	Returns the sum of its inputs
$x - y$	Returns the difference of its inputs
$x * y$	Returns the product of its inputs
$\{x,y\}$	Returns the mean of its inputs
$\min\{x,y\}$	Returns the lesser of its inputs
$\max\{x,y\}$	Returns the greater of its inputs
$-x$	Returns its input multiplied by -1

94

## Overview



95

## Planning Your Own Study

- ❖ Determine the *real* clinical need
  - and the potential for commercialisation
- ❖ Identify clinical collaborators
- ❖ Design a clinical protocol
- ❖ Protect intellectual property
- ❖ Apply for ethical approval
- ❖ Obtain regulatory compliance
- ❖ Undertake clinical studies
- ❖ Processing data

96

### *Determine the Real Clinical Need*

- ❖ *Not* searching for a need for the technology you have developed
- ❖ Speak to the users
  - doctors, nurses and patients
- ❖ Try to evaluate:
  - improved quality of life
  - cost savings/other benefits

97

### *Potential for Commercialisation*

- ❖ Consider commercialisation at the outset
  - establish what is needed and will be useful
  - gets the technology to the patient
  - raises funding for development
    - and further research
- ❖ The process itself can have value

98

### *Identifying Clinical Collaborators*

- ❖ Essential for:
  - data
  - establishing the justification of the work
  - obtaining sufficient patient numbers
  - obtaining clinical acceptance
  - provide clinical interpretation of results

99

### *Designing a Clinical Protocol*

- ❖ Should be clinically led
  - beware of mission creep/other clinical interests
  - needs to establish ground truth through conventional clinical tests
  - consider engaging a clinical trial unit
- ❖ Principal and secondary research questions
- ❖ Participant sample size
  - with statistical justification
- ❖ Inclusion/exclusion criteria
- ❖ End points

100

## *Datasets*

- ❖ If using existing data determine its:
  - suitability
  - integrity
- ❖ If no existing datasets available
  - need to acquire patient measurement
  - ethical approval required
  - sensors may also require regulatory approval

101

## *Applying for Ethical Approval*

- ❖ Scientific justification
- ❖ Clinical protocol
- ❖ Participant recruitment procedures
  - participant information sheet
  - informed consent
- ❖ Research may need to undergo external review

102

## *Protect Intellectual Property*

- ❖ Not as difficult as it sounds!
  - initial filing
  - PCT
  - International Phase
- ❖ Engage a good patent attorney
- ❖ Essential for getting attention
  - and securing further funding

103

## *Regulatory Compliance*

- ❖ Consider then need for regulatory compliance
- ❖ Sometimes required to undertake clinical studies
  - required before sales can begin
  - often based on self-certification
- ❖ Different regulatory bodies for different countries
  - all based on same ISO standards

104

## *Undertake Preliminary Clinical Studies*

- ❖ Small proof of concept study
  - validates the technology
  - helps determine the clinical need
  - highlights problems/modifications
  - gains supporters/champions

105

## *Analysing Data*

- ❖ Choose an appropriate algorithm
- ❖ Consider adopting clinically accepted measures
- ❖ Use k-fold cross-validation when dealing with small patient numbers
- ❖ Ensembles can be effective in increasing classification performance

106


## *Avoid Common Pitfalls*

- ❖ Don't touch the patients (or their data)!
  - until you have the necessary ethical approval/consent
  - and possibly other statutory authority
- ❖ Be careful what you offer
  - work takes time and consultants can be demanding!
- ❖ Expect to do all the running
  - medics are busy
  - many not be used to applying for grants
  - or writing long papers

107

## *Useful Resources*

### ❖ Books



108

## *Useful Resources*

### ❖ Journals

- IEEE Transactions on Evolutionary Computation
- Genetic Programming and Evolvable Machines
- IEEE Transactions on Neural Systems and Rehabilitation Engineering
- BioSystems
- International Journal of Computers in Healthcare

109

## *Useful Resources*

### ❖ Conferences

- IEEE Symposium Series on Computational Intelligence (SSCI) Workshop on Computational Intelligence in Medical Imaging (CIMI)
- Genetic and Evolutionary Computation Conference (GECCO) Medical Applications of Genetic and Evolutionary Computation (MedGEC)

110

## *Possible Benefits*

### ❖ More publications

- in engineering and medical journals

### ❖ More funding sources

- government grants
- basic & applied research and knowledge transfer
- charities
- patents and spin-out companies!

### ❖ More fun!

111

## *Summary*

### ❖ Medical applications of EC rely on:

- good collaborations
- good data
- appropriate evolutionary algorithms

112

## References

1. Leonardo Bocchi. 2003. Multiple genetic snakes for bone segmentation. In Proceedings of the 2003 international conference on Applications of evolutionary computing (EvoWorkshops'03), Stefano Cagnoni, Colin G. Johnson, Elena Marchiori, David W. Corne, and Jens Gottlieb (Eds.). Springer-Verlag, Berlin, Heidelberg, 346-356.
2. Gabriel Mañana, Fabio González, and Eduardo Romero. 2005. Distributed genetic algorithm for subtraction radiography. In *Proceedings of the 2005 workshops on Genetic and evolutionary computation (GECCO '05)*. ACM, New York, NY, USA, 140-146. DOI=10.1145/1102256.1102288 <http://doi.acm.org/10.1145/1102256.1102288>
3. Ghannad-Rezaie, M., Soltanain-Zadeh, H., Siadat, M.-R. and Elisevich, K.V. 2006. Medical data mining using particle swarm optimization for temporal lobe epilepsy. *IEEE Congress on Evolutionary Computation (CEC) 2006*, pp. 761-768.
4. Alderliesten, T., Bosman, P.A.N., Niessen, W.J. 2007. "Towards a Real-Time Minimally-Invasive Vascular Intervention Simulation System," *Medical Imaging, IEEE Transactions on*, vol. 26, no. 1, pp. 128-132, doi: 10.1109/TMI. 2006.886814 URL: <http://ieeexplore.ieee.org/stamp/stamp.jsp?tp=&arnumber=4039522&isnumber=4039521>
5. Koutsojannis, C. and Hatzilygeroudis, I. 2006. Fuzzy-evolutionary synergism in an intelligent medical diagnosis system. *Knowledge-Based Intelligent Information and Engineering Systems. 10th International Conference, KES 2006. Proceedings, Part II. Lecture Notes in Artificial Intelligence*, Vol. 4252. Springer-Verlag, pp. 1305-1312.
6. D. Hope, S. Smith, and E. Munday, "Evolutionary algorithms in the classification of mammograms," in *IEEE Symposium on Computational Intelligence in Image and Signal Processing*, pp. 258-265, 2007.
7. J.Walker, K. Völz, S. Smith, and J. Miller, "Parallel evolution using multi-chromosome Cartesian genetic programming," *Genetic Programming and Evolvable Machines*, vol. 10, no. 4, 2009.
8. M. A. Lones, S. L. Smith, A. T. Harris, A. S. High, S. E. Fisher, D. A. Smith and J. Kirkham, "Discriminating Normal and Cancerous Thyroid Cell Lines using Implicit Context Representation Cartesian Genetic Programming," *Proc. World Congress on Computational Intelligence (WCCI) 2010, Barcelona*, IEEE Press, 2010.

113

